Shilpa Medicare Ltd (SHILPAMED)
₹672.05▲4.44%
Shilpa Medicare Ltd Share analysis
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹641.6₹67552 Week's Low
52 Week's High
₹296.8₹685
| Returns % | |
| 1 Month Return | + 7.93 % |
| 3 Month Return | + 21.15 % |
| 1 Year Return | + 104.21 % |
| Market Stats | |
| Previous Close | ₹643.45 |
| Open | ₹647.00 |
| Volume | 3.03L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹6,292.36Cr |
Key Statistics
| P/E Ratio | 174.85 |
| PEG Ratio | 23.56 |
| Market Cap | ₹6,292.36 Cr |
| P/B Ratio | 0.94 |
| EPS | 13.43 |
Peer Comparison
Mutual Fund Holdings
Company Information
Share Price: ₹672.05 per share as on 24 Jul, 2024 04:01 PM
Market Capitalisation: ₹6,292.36Cr as of today
Revenue: ₹291.69Cr as on March 2024 (Q1 24)
Net Profit: ₹24.50Cr as on March 2024 (Q1 24)
Listing date: 03 Dec, 2009
Chairperson Name: Omprakash Inani
| Organisation | Shilpa Medicare Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Shilpa Medicare Ltd
Shilpa Biologicals Receives Approval for Adalimumab from Morocco - 23 Jul, 2024
Shilpa Biologicals, a subsidiary of Shilpa Medicare, has received approval for its high concentration Adalimumab biosimilar from the Moroccan Ministry of Health. This is the first international market approval for the drug, and the company plans to submit dossiers in more than 15 emerging markets.
Shilpa Medicare Reports Revenue Growth and Profit in FY24 - 17 Jul, 2024
Shilpa Medicare Limited's Revenue from Operations grew by 10.08% to Rs. 1,152 Crores in FY24, accompanied by a profit of Rs. 32 Crores. FII/FPI increased their holding in Q1FY25.
Shilpa Medicare Passes GMP Inspections - 10 Jul, 2024
Shilpa Medicare's subsidiary, Shilpa Pharma Lifesciences, and its Raichur API facility pass GMP inspections by Brazilian and Global Regulatory Authorities respectively. The company reports a consolidated net profit of Rs 24.50 crore in Q4 FY24.
Shilpa Medicare Shares Surge on Positive Clinical Trial Results - 05 Jul, 2024
Shilpa Medicare's stock surged up to 16.25% following positive clinical trial results for its kidney disease drug. The company partnered with Unicycive to provide end-to-end CDMO services and is set to receive $10M milestone income. Additionally, one of its subsidiaries acquired a stake in Mylab Discovery Solutions Limited. Despite slower-than-industry revenue growth, investors are hoping for a turnaround in the company's business prospects.
Shilpa Medicare Insiders Show Vested Interest in Company's Growth - 26 Jun, 2024
Insiders own 51% of Shilpa Medicare, with CEO Vishnukanth Bhutada increasing holdings by 10%. Institutional investors also have a fair amount of stake. Private companies own 8.7%.
Shilpa Medicare Facility Passes US FDA Inspection - 25 Jun, 2024
Shilpa Medicare's Bio-Analytical Laboratory in Hyderabad, India passed a US FDA inspection with no observations and was classified as No Action Indicated (NAI). The company reported a net profit of Rs 24.50 crore in Q4 FY24.
Insights on Shilpa Medicare Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 5 quarters, -8.04 Cr → 24.5 Cr (in ₹), with an average increase of 238.6% per quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, SHILPAMED has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 38.39% to 38.92% in Jun 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 6 months, SHILPAMED stock has moved up by 100.5%
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 5.01% to 5.03% in Jun 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 288.7 Cr → 300.32 Cr (in ₹), with an average increase of 3.9% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 44.39% of holdings in Jun 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 127.7% return, outperforming this stock by 128.7%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 9.68% to 9.08% in Jun 2024 quarter
Company Financials
| Q'1 24 | Q/Q Change | |
|---|---|---|
Revenue | ₹291.69Cr | ↑1.72% |
Net Income | ₹24.50Cr | ↑421.28% |
Net Profit Margin | 8.40% | ↑412.20% |
| 2023 | Y/Y Change | |
|---|---|---|
Revenue | ₹1,050.11Cr | ↓8.33% |
Net Income | -₹30.92Cr | ↓151.04% |
Net Profit Margin | -2.94% | ↓155.58% |
| 2023 | Y/Y Change | |
|---|---|---|
Total Assets | ₹2,595.86Cr | ↓12.48% |
Total Liabilities | ₹478.28Cr | ↓46.88% |
| 2023 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | ₹2.08Cr | ↓98.80% |
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 44.39% | 0.00 | |
| Foreign Institutions | 9.08% | ||
| Mutual Funds | 5.03% | 0.39 | |
| Retail Investors | 38.92% | 1.38 | |
| Others | 2.58% | 2.06 |
Key Indicators
Shilpa Medicare Ltd Valuation
Shilpa Medicare Ltd in the last 5 years
Lowest (-6579.29x)
March 28, 2024
Industry (56.07x)
July 23, 2024
Today (174.85x)
July 23, 2024
Highest (503.73x)
February 21, 2023
Earnings and Dividends
Shilpa Medicare Ltd Earnings Results
Shilpa Medicare Ltd’s net profit jumped 404.73% since last year same period to ₹24.50Cr in the Q4 2023-2024. On a quarterly growth basis, Shilpa Medicare Ltd has generated 434.93% jump in its net profits since last 3-months.
Read More about Earnings ResultsShilpa Medicare Ltd Dividends May,2022
In the quarter ending March 2022, Shilpa Medicare Ltd has declared dividend of ₹1.10 - translating a dividend yield of 0.34%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Shilpa Medicare Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Shilpa Medicare Ltd shares.
Shilpa Medicare Ltd (SHILPAMED) share price today is ₹672.05
Shilpa Medicare Ltd is listed on NSE
Shilpa Medicare Ltd is listed on BSE
- Today’s highest price of Shilpa Medicare Ltd is ₹675.
- Today’s lowest price of Shilpa Medicare Ltd is ₹641.6.
PE Ratio of Shilpa Medicare Ltd is 174.85
PE ratio = Shilpa Medicare Ltd Market price per share / Shilpa Medicare Ltd Earnings per share
Today’s traded volume of Shilpa Medicare Ltd(SHILPAMED) is 3.03L.
Today’s market capitalisation of Shilpa Medicare Ltd(SHILPAMED) is ₹6292.36Cr.
| Shilpa Medicare Ltd(SHILPAMED | Price |
|---|---|
52 Week High | ₹685 |
52 Week Low | ₹296.8 |
Shilpa Medicare Ltd(SHILPAMED) share price is ₹672.05. It is down -1.89% from its 52 Week High price of ₹685
Shilpa Medicare Ltd(SHILPAMED) share price is ₹672.05. It is up 126.43% from its 52 Week Low price of ₹296.8
| Shilpa Medicare Ltd(SHILPAMED | Returns |
|---|---|
1 Day Returns | 28.6% |
1 Month Returns | 7.93% |
3 Month Returns | 21.15% |
1 Year Returns | 104.21% |